Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

10x Genomics (TXG) Accumulated Depreciation & Amortization (2018 - 2025)

10x Genomics' Accumulated Depreciation & Amortization history spans 8 years, with the latest figure at $36.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 0.89% year-over-year to $36.2 million; the TTM value through Dec 2025 reached $36.2 million, up 0.89%, while the annual FY2025 figure was $36.2 million, 0.89% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $36.2 million at 10x Genomics, up from $26.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $36.2 million in Q4 2025 and bottomed at $4.8 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $18.2 million (2024), against an average of $19.4 million.
  • The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 51.94% in 2021 before it dropped 12.82% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $21.1 million in 2021, then rose by 20.13% to $25.4 million in 2022, then surged by 39.99% to $35.5 million in 2023, then increased by 1.03% to $35.9 million in 2024, then grew by 0.89% to $36.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Accumulated Depreciation & Amortization are $36.2 million (Q4 2025), $26.1 million (Q3 2025), and $15.8 million (Q2 2025).